1Operating loss improved to -$26.7M (from -$58.4M in FY2024), reflecting lower costs from winding down the mBC trial and reduced enrollment in the IPF study.
2Net loss narrowed significantly to -$18.2M (from -$70.9M in FY2024), a 74.3% year-over-year improvement, due to decreased R&D spending and true-up adjustments.
3Diluted EPS was $-3.26, a substantial improvement from $-15.53 in FY2024, aligning with overall reduction in net loss.
4Net cash used in operating activities decreased to -$23.5M (from -$60.9M in FY2024), indicating better cash efficiency despite ongoing negative cash flow.
5The company has not generated any product revenue since inception and continues to rely entirely on equity financing to fund operations.
6G&A expenses include professional services, insurance, and facility-related costs, with no significant changes reported in this period.
7Future R&D spending is expected to increase as TTI-101 and TTI-109 development progresses, requiring additional capital to sustain planned activities.